Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS...

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Interferon beta therapy is established for multiple sclerosis (MS).
• Its efficacy when initiated at a first clinical demyelinating event remains unclear.
• Subclinical demyelination on MRI may identify at-risk individuals.

Purpose of the Study:

• To determine if early interferon beta-1a treatment benefits patients after a first demyelinating event.
• To assess the impact of early treatment on the development of clinically definite MS.
• To evaluate treatment effects on MRI-detected brain lesions.

Main Methods:

• A randomized, double-blind, placebo-controlled trial.
• 383 patients with a first demyelinating event and MRI evidence of prior demyelination were enrolled.
• Patients received corticosteroids followed by weekly intramuscular interferon beta-1a or placebo for three years.

Main Results:

• Interferon beta-1a significantly reduced the cumulative probability of developing clinically definite MS over three years (rate ratio 0.56, P=0.002).
• Patients receiving interferon beta-1a showed significant reductions in brain lesion volume, new/enlarging lesions, and gadolinium-enhancing lesions at 18 months (P<0.001 for all).

Conclusions:

• Initiating interferon beta-1a treatment at the time of a first demyelinating event is beneficial.
• Early treatment is recommended for patients with MRI evidence of brain lesions indicating high MS risk.